Jupiter Neurosciences Inc... (JUNS)
NASDAQ: JUNS
· Real-Time Price · USD
0.66
-0.01 (-1.49%)
At close: Apr 28, 2025, 3:59 PM
0.65
-2.14%
After-hours: Apr 28, 2025, 06:40 PM EDT
-1.49% (1D)
| Bid | 0.61 |
| Market Cap | 21.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.44M |
| EPS (ttm) | -0.08 |
| PE Ratio (ttm) | -8.3 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.7 |
| Volume | 28,993 |
| Avg. Volume (20D) | 219,286 |
| Open | 0.69 |
| Previous Close | 0.67 |
| Day's Range | 0.63 - 0.69 |
| 52-Week Range | 0.51 - 19.51 |
| Beta | -9.92 |
About JUNS
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 18, 2022
Employees 4
Stock Exchange NASDAQ
Ticker Symbol JUNS
Website https://www.jupiterorphan.com